Advances in kidney disease and health最新文献_第5页

Electrolyte and Acid-Base Abnormalities After Kidney Transplantation 肾移植后的电解质和酸碱异常

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.03.007

Patricia Nogueira de Sa , Mohanram Narayanan , Mary Ann C. Lim

引用次数: 0

Biomarkers in Kidney Transplantation 肾移植中的生物标记物

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.06.001

Ashish Kataria , Akshay Athreya , Gaurav Gupta

{"title":"Biomarkers in Kidney Transplantation","authors":"Ashish Kataria , Akshay Athreya , Gaurav Gupta","doi":"10.1053/j.akdh.2024.06.001","DOIUrl":"10.1053/j.akdh.2024.06.001","url":null,"abstract":"<div><p>Currently in the United States, there are more than 250,000 patients with a functioning kidney allograft and over 100,000 waitlisted patients awaiting kidney transplant, with a burgeoning number added to the kidney transplant wait list every year. Although early post-transplant care is delivered at the transplant center, the increasing number of kidney transplant recipients requires general nephrologists to actively participate in the long-term care of these patients. Serum creatinine and proteinuria are imperfect traditional biomarkers of allograft dysfunction and lag behind subclinical allograft injury. This manuscript reviews the various clinically available biomarkers in the field of kidney transplantation for a general nephrologist with a focus on the utility of donor-derived cell-free DNA, as a marker of early allograft injury. Blood gene expression profiling, initially studied in the context of early identification of subclinical rejection, awaits validation in larger multicentric trials. Urinary cellular messenger ribonucleic acid and chemokine CXCL10 hold promising potential for early diagnosis of both subclinical and acute rejection. Torque tenovirus, a ubiquitous DNA virus is emerging as a biomarker of immunosuppression exposure as peripheral blood torque tenovirus copy numbers might mirror the intensity of host immunosuppression. Although high-quality evidence is still being generated, evidence and recommendations are provided to aid the general nephrologist in implementation of novel biomarkers in their clinical practice.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 5","pages":"Pages 427-435"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Kidney Transplant Journey: Passing the Baton From Transplant Nephrologists to Referring Nephrologist 肾移植之旅：移植肾科医生向转诊肾科医生传授经验

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.07.002

Scott G. Westphal, Bassam G. Abu Jawdeh, Anju Yadav

引用次数: 0

Kidney Transplant Candidacy: Addressing Common Medical and Psychosocial Barriers to Transplant 肾移植候选者：解决移植常见的医疗和社会心理障碍

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.03.002

Brian Benes, Eric D. Langewisch, Scott G. Westphal

引用次数: 0

Approach to Kidney Allograft Dysfunction: A Brief Review 治疗肾移植功能障碍的方法：简要回顾

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.06.002

Kanza Haq , Anju Yadav , Christina Mejia

引用次数: 0

Coronavirus Disease 2019 in Kidney Transplantation – A 2024 Update 2019年肾移植中的冠状病毒疾病--2024年最新进展

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.03.004

Bassam G. Abu Jawdeh , Holenarasipur R. Vikram

{"title":"Coronavirus Disease 2019 in Kidney Transplantation – A 2024 Update","authors":"Bassam G. Abu Jawdeh , Holenarasipur R. Vikram","doi":"10.1053/j.akdh.2024.03.004","DOIUrl":"10.1053/j.akdh.2024.03.004","url":null,"abstract":"<div><p>The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 has led to the death of about 7 million people worldwide. When infected, older individuals and those with diabetes, hypertension, cardiovascular disease, and compromised immune system are at higher risk for unfavorable outcomes. These comorbidities are prevalent in kidney transplant candidates and recipients making them inherently vulnerable to severe acute respiratory syndrome coronavirus 2 infection, hence, the significant burden the pandemic has exerted on kidney transplant programs. With the swift discovery and wide-scale availability of vaccines and therapeutics against severe acute respiratory syndrome coronavirus 2, the pandemic is currently behind us allowing transplant programs to relieve their restrictions and resume normal pre-COVID-19 operations. In the aftermath of the pandemic, we discuss the implications for immunosuppression and vaccination, COVID-19–induced kidney injury phenotypes and long COVID-19 symptoms. We also discuss some of the operational aspects the pandemic brought about – mainly the utilization of telemedicine – that are now here to stay.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 5","pages":"Pages 458-465"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approach to Late Noninfectious Post-Transplant Complications 处理移植后晚期非感染性并发症的方法

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.05.005

Sami Alasfar, Hay Me Me, Pooja Budhiraja

{"title":"Approach to Late Noninfectious Post-Transplant Complications","authors":"Sami Alasfar, Hay Me Me, Pooja Budhiraja","doi":"10.1053/j.akdh.2024.05.005","DOIUrl":"10.1053/j.akdh.2024.05.005","url":null,"abstract":"<div><p>The management of noninfectious complications in kidney transplant recipients includes a broad spectrum of conditions, including metabolic issues, cardiovascular diseases, and malignancies, each presenting unique challenges for nephrologists managing these patients. Unlike infectious complications, these noninfectious issues require nuanced, multidisciplinary approaches for prevention, diagnosis, and management, emphasizing the need for personalized care plans. Cardiovascular disease is particularly significant, standing as the primary cause of death post-transplantation, with recent data indicating an overtaking of cancer death rates over infections among kidney transplant recipients. The intricacies of managing these patients, influenced by the burden of kidney disease and immunosuppression, highlight the importance of a collaborative care model. Although nephrologists may not directly treat all these conditions, their understanding of the unique aspects of transplant recipients is crucial. They play a pivotal role in coordinating care with specialists such as cardiologists, endocrinologists, hematologists, and oncologists, ensuring comprehensive management that addresses these specific post-transplant complications. This review discusses the epidemiology, underlying mechanisms, clinical manifestations, and management strategies of various noninfectious complications post-kidney transplant, with a focus on cardiovascular, metabolic, oncologic, and hematologic complications.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 5","pages":"Pages 436-449"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation and Long-Term Follow-Up of Living Kidney Donors 活体肾脏捐献者的评估和长期随访

Advances in kidney disease and health Pub Date : 2024-09-01 DOI: 10.1053/j.akdh.2024.04.003

Katafan A. Achkar , Lama M. Abdelnour , Bassam G. Abu Jawdeh , Ekamol Tantisattamoa , Fawaz Al Ammary

{"title":"Evaluation and Long-Term Follow-Up of Living Kidney Donors","authors":"Katafan A. Achkar , Lama M. Abdelnour , Bassam G. Abu Jawdeh , Ekamol Tantisattamoa , Fawaz Al Ammary","doi":"10.1053/j.akdh.2024.04.003","DOIUrl":"10.1053/j.akdh.2024.04.003","url":null,"abstract":"<div><p>The evaluation of living kidney donor candidates is a complex and lengthy process. Donor candidates face geographic and socioeconomic barriers to completing donor evaluation. Inequities in access to living donations persist. With a growing demand for kidney transplants and a shortage of living donors, transplant centers are more permissive of accepting less-than-ideal donor candidates. Donors have an increased lifetime risk of kidney failure, but the absolute risk increase is small. Efforts are needed to support donor candidates to complete donor nephrectomy safely and efficiently and receive optimal follow-up care to prevent risk factors for kidney disease and detect complications early. In this article, the authors address key elements of donor kidney evaluation, including current living donation policy requirements and transplant center practices. The authors present a simplified comprehensive practical approach to help guide providers in completing donor evaluation and follow-up care with best outcomes possible.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 5","pages":"Pages 400-407"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949813924000739/pdfft?md5=95256588bf60e85ca91544b9c6c1f540&pid=1-s2.0-S2949813924000739-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities 非免疫球蛋白淀粉样变性肾病：对诊断不足实体的新认识。

Advances in kidney disease and health Pub Date : 2024-07-01 DOI: 10.1053/j.akdh.2024.02.001

Sabine Karam , Amit Kaushal , Nabil Abu Amer , Virginie Royal , Abhijat KItchlu

{"title":"Non-Immunoglobulin Amyloidosis-Mediated Kidney Disease: Emerging Understanding of Underdiagnosed Entities","authors":"Sabine Karam , Amit Kaushal , Nabil Abu Amer , Virginie Royal , Abhijat KItchlu","doi":"10.1053/j.akdh.2024.02.001","DOIUrl":"10.1053/j.akdh.2024.02.001","url":null,"abstract":"<div><p>Amyloidosis is a complex group of rare disorders characterized by the deposition of misfolded proteins in the extracellular space of various tissues and organs, leading to progressive organ dysfunction. The kidneys constitute a very common site affected, most notably by immunoglobulin-mediated (light chain, heavy chain, and light and heavy chain amyloidosis), but other types that include serum amyloid A (AA) amyloidosis and leukocyte chemotactic factor 2 amyloidosis, along with mutant proteins in several hereditary forms of amyloidosis such as transthyretin, fibrinogen α-chain, gelsolin, lysozyme, and apolipoproteins AI/AII/AIV/CII/CIII amyloidosis have been incriminated as well. The clinical presentation is variable and can range from minimal proteinuria for leukocyte chemotactic factor 2 amyloidosis to a full-blown nephrotic syndrome for AA amyloidosis. Clinical correlation, genetic analysis, and adequate tissue typing through a kidney biopsy are essential to make the correct diagnosis, especially when a family history of amyloidosis is absent. Except for AA and transthyretin amyloidosis, the treatment is usually purely supportive. Kidney transplantation is an acceptable form of treatment for end-stage kidney disease in all types of non-Ig-mediated renal amyloidosis.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 4","pages":"Pages 334-345"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Membranous Nephropathy: Updates on Management 膜性肾病：管理更新。

Advances in kidney disease and health Pub Date : 2024-07-01 DOI: 10.1053/j.akdh.2024.04.004

Joyita Bharati , Dia Rose Waguespack , Laurence H. Beck Jr.

{"title":"Membranous Nephropathy: Updates on Management","authors":"Joyita Bharati , Dia Rose Waguespack , Laurence H. Beck Jr.","doi":"10.1053/j.akdh.2024.04.004","DOIUrl":"10.1053/j.akdh.2024.04.004","url":null,"abstract":"<div><p>Membranous nephropathy is a major etiology of nephrotic syndrome in adults and less frequently in children. Circulating antibodies to intrinsic podocyte antigens, such as M-type phospholipase A2 receptor, or to extrinsic proteins accumulate beneath the podocyte to cause damage via complement activation and/or other mechanisms. The availability of clinical testing for autoantibodies to M-type phospholipase A2 receptor has allowed noninvasive diagnosis of this form of membranous nephropathy and a means to monitor immunologic activity to guide immunosuppressive therapy. Treatment of membranous nephropathy includes optimal supportive care with renin-angiotensin-system blockers, lipid-lowering agents, diuretics, lifestyle changes, and additional immunosuppressive therapy in patients with an increased risk of progression to kidney failure. Rituximab has been recognized as a first-line immunosuppressive therapy for most membranous nephropathy patients with an increased risk of progressive disease, except those with life-threatening nephrotic syndrome or rapidly deteriorating kidney function from membranous nephropathy. This article discusses the major and minor antigens described in membranous nephropathy, the natural history of the disease, and guidelines for clinical management and immunosuppressive treatment.</p></div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"31 4","pages":"Pages 299-308"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0